CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
esomeprazole +1 moredrug
Likely dose
esomeprazole 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00719160
NCT00719160Phase 4Completed
CompareCT.gov

Dietary Protein's Effect on Gastric pH and Calcium Absorption

Yale University·interventional·Posted Jul 21, 2008·Updated Mar 6, 2020

In Brief

A Phase 4 clinical trial evaluating esomeprazole and Placebo for Osteoporosis. Completed, enrolled 12 participants across 1 site.

Detailed Summary

We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether dietary protein-induced changes in gastric acid secretion explain the observed changes in intestinal calcium absorption.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 21, 2008
Enrollment StartJan 1, 2005
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.9 years ago

Interventions

esomeprazoledrug

2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet

Placebodrug

Placebo 20 mg twice a day for 9 days